Aluminium oxyhydroxide (alum), a nanocrystalline compound forming agglomerates, has been used in vaccines for its immunological adjuvant effect since 1927. Alum is the most commonly used adjuvant in human and veterinary vaccines, but the mechanisms by which it stimulates immune responses remain incompletely understood. Although generally well tolerated, alum may occasionally cause disabling health problems in presumably susceptible individuals. A small proportion of vaccinated people present with delayed onset of diffuse myalgia, chronic fatigue and cognitive dysfunction, and exhibit very long-term persistence of alum-loaded macrophages at the site of previous intramuscular (i.m.) immunization, forming a granulomatous lesion called macrophagic myofasciitis (MMF). Clinical symptoms associated with MMF are paradigmatic of the recently delineated 'autoimmune/inflammatory syndrome induced by adjuvants' (ASIA). The stereotyped cognitive dysfunction is reminiscent of cognitive deficits described in foundry workers exposed to inhaled Al particles. Alum safety concerns will largely depend on whether the compound remains localized at the site of injection or diffuses and accumulates in distant organs. Animal experiments indicate that biopersistent nanomaterials taken up by monocyte-lineage cells in tissues, such as fluorescent alum surrogates, can first translocate to draining lymph nodes, and thereafter circulate in blood within phagocytes and reach the spleen, and, eventually, slowly accumulate in the brain. Lupus (2012) 21, 184-189.
Introduction
In 1998, a consortium of French myopathologists described an emerging condition of unknown cause characterized by a pathognomonic lesion at muscle biopsy we called macrophagic myofasciitis (MMF). 1 MMF was detected in middle-aged adult patients with diffuse myalgias and fatigue. 1 Macrophages were the major cell type in the lesion, and enclosed agglomerates of nanocrystals in their cytoplasm. 1 Subsequently, these inclusions proved to be a key finding, as they were consistently present on electron microscopy, and conspicuously contained aluminium, as shown by ionic or X-ray microanalysis. 2 MMF was typically detected in the deltoid muscle, and could be differentiated both clinically and pathologically from Whipple's disease and other infectious histiocytoses, and from diffuse dysimmune fasciitis and panniculitis. 3 The crystalline rather than amorphous ultrastructural appearance of the inclusions was suggestive of aluminium hydroxide. Patients had normal renal function and had no particular exposure to aluminium other than previous immunization against hepatitis B (HBV), hepatitis A (HAV) or tetanus toxoid (TT) vaccines (100%), thus strongly suggesting that MMF inclusions correspond to aluminium oxyhydroxide (alum), an adjuvant incorporated in these vaccines to boost immunological responses. 2 It is now clear that the rapid emergence of MMF in France resulted from the specific combination of three factors: (1) replacement of the subcutaneous (s.c.) route by the intramuscular (i.m.) route of vaccination in the early 1990s; (2) widespread extension of HBV primovaccination to the French adult population at the same time; and (3) the choice of the deltoid muscle (also used for i.m. vaccination) for routine muscle biopsy in France, whereas biceps brachialis and quadriceps femoris muscles are preferred in most other countries. The MMF lesion is now universally recognized as signifying long-term persistence of alum at the site of previous i.m. immunization. 4 However, alum has been generally considered as safe on the basis of short-term surveys, and the exact significance of longstanding MMF detection in a given patient remains uncertain because of (i) apparently 'poorly specific' clinical manifestations, which of course does not mean non-disabling ones, and (ii) lack of a self-evident link between persistence of alum agglomerates in macrophages at sites of immunization and delayed onset of systemic and neurological manifestations. The formal delineation of 'autoimmune/inflammatory syndrome induced by adjuvants' (ASIA) 5 and novel insights into the biodistribution of slowly biodegradable particles taken up by monocyte-lineage cells in peripheral tissues provide the basis for a better understanding of this rare adverse effect of alum.
MMF histopathology
Deltoid muscle biopsy findings are stereotyped, [1] [2] [3] [4] consisting of focal infiltration of the epimysium, perimysium and perifascicular endomysium by well-circumscribed and cohesive sheets of large mononucleated cells of the monocyte and macrophage lineage, usually intermingled with a minor lymphocytic population. The maximum observed section size of the lesion is 1 cm. Aluminium salts are positively stained by haematoxylin and, consistently, the cytoplasm of macrophages is basophilic (dark blue) on haematoxylin-eosin-stained cryostat sections. Probably due to specific chemical reactions, this is not observed in formalin-fixed material, in which macrophages exhibit a finely granular grey/beige content. In both cryostat and paraffin sections, macrophages are strongly periodic acid Schiff (PAS) positive. They express CD68 and major histocompatibility complex (MHC) class 1 and MHC class 2 antigens. CD3 þ T cells, mainly CD8 þ , forming perivascular cuffs are consistently found. Occasional CD19 þ B cells, rarely forming lymphoid follicles, and CD138 þ plasma cells may be detected. Giant multinucleated cells are not detected except when another foreign material, for example cotton wool, is present. In rare instances (about 1%) the granuloma may be encircled by thick fibrotic tissue and centred with a large necrotic area, forming a lesion reminiscent of a rheumatoid nodule. Myofibres remote from the infiltrate are typically intact, but MMF may be occasionally associated with typical dermatomyositis or autoimmune necrotizing myopathy. On electron microscopy, macrophages appear heavily loaded with submicron/micron-sized agglomerates of spiculated osmiophilic structures surrounded by discontinuous lysosomal membranes. Inclusions can be routinely visualized by the Morin stain for aluminium. Microorganisms are not detected by appropriate staining or electron microscopy.
Similar MMF lesions can be detected in the quadriceps muscle in babies and children, because this muscle is used for i.m. vaccine administration in young individuals. MMF can be experimentally reproduced by i.m. vaccination in mice, rats and monkeys, 2,6,7 progressively shrinking with time. 6 It is, therefore, important to determine whether the MMF lesion is unusually persistent in biopsied patients by precisely recapitulating history of previous vaccinations. In practice we consider MMF to be persistent when the time elapsed from the last vaccine shot to MMF detection is >18 months. This point is particularly important in small children, who receive numerous alum-containing vaccine shots in the first year of life, increasing the risk of chance associations between MMF lesions and unrelated conditions, such as congenital myopathies and muscular dystrophies. 8 The risk also exists in adults, but accounts for no more than 5-10% of MMF-positive biopsies, including fully asymptomatic patients and patients investigated for hereditary disorders.
In contrast to i.m. injections, alum-containing vaccines administered by the s.c. route may elicit chronic lesions that are somewhat different from MMF, so-called cutaneous pseudo-lymphoma, associated with a rim of alum-containing macrophages. 9 From MMF-associated syndrome to ASIA According to the patients' association, about 1000 patients with documented MMF have been identified in France. Occasional cases have been reported in many other countries. 8, [10] [11] [12] [13] [14] [15] The structure of symptoms was strikingly similar in independent cohorts of French adult patients. 4 We recently reviewed the files of 457 adult MMF patients collected from 1994 to 2011 in our centre. Patients were either investigated and biopsied (n ¼ 270) at the Neuromuscular Centre of Cre´teil (Neuromuscular Reference Centre Garches-Necker-Mondor-Hendaye) or referred for followup or complementary investigation after MMF detection in other French hospitals by one of the myopathologists who had described the lesion (n ¼ 187). Most patients were female (70%) and middle-aged at time of biopsy (median 45 years, range 12-83). They had received 1 to 17 i.m. alum-containing vaccine administrations (mean 5.3) in the 10 years before MMF detection, and these included HBV vaccination in 85%. Patients mainly complained of chronic diffuse myalgias >6 months (89%) with or without arthralgias, disabling chronic fatigue >6 months (77%), overt cognitive alterations affecting memory and attention (51%), and dyspnoea (50%). As previously reported, onset of these clinical symptoms was always delayed after immunization, the median time elapsed from last vaccine administration being 7 months (range 0.5-84) for initial systemic symptoms and 11 months (range 0-72) for first myalgia. 4 Time elapsed from last vaccine administration to biopsy was 65 months (range 3-219). Compared with our previous reports, this delay has progressively increased (36 months in the initial series of 2001, 53 months in the series of 2003), 4 indicating that MMF patients have a chronic disease and, though mainly vaccinated in the late 1990s or early 2000s, were frequently diagnosed long after the onset of symptoms.
Myalgias and fatigue may not be synchronous. Myalgia may follow exercise of unusual intensity; it often begins in the lower limbs, 4 and almost never at the site of previous vaccine injection. Myalgia progressively extends upwards to affect the paravertebral muscles and becomes diffuse by the time of biopsy. 4 Muscle weakness is rare. Myopathic electromyogram and creatine kinase (CK) elevation are found in fewer than half of patients. Some fibromyalgic tender points are detected in a minority of patients, but the 1990 ACR criteria for fibromyalgia are rarely fulfilled. 4 Interestingly, 67 Gallium scintigrams have shown the presence of subtle radionuclide uptake predominating in the painful areas along the lower limb muscle fascias and in para-articular tissues in all tested patients. 17 This was not found in fibromyalgic controls.
Fatigue, sleep disturbances with unrefreshing sleep, and sometimes headaches may be very disabling and often deeply impact professional and personal life. A case-control study conducted by Agence Franc¸aise de Securite´Sanitairedes Produits de Sante´(AFSSAPS) pointed out chronic fatigue as being more frequent and more pronounced in patients with than without MMF in deltoid muscle (http://afssaps.sante.fr/htm/10/myofasci/etude.pdf). In fact, a majority of patients fulfil international criteria of chronic fatigue syndrome (CFS). 18 Consequently, history of exposure to alum-containing vaccines should be checked carefully in patients with CFS, and muscle biopsy to determine persistent MMF at site of injection should be considered when the chronology is consistent, even many years after onset of symptoms.
Central nervous system involvement is assessed by cognitive dysfunction. Patients complain of subjective memory impairment, difficulties in sustaining attention, and mood disturbances. Although often disabling, cognitive dysfunction is often underestimated or remains undetected by routine examination. A comprehensive battery of neuropsychological tests in unselected MMF patients without multiple sclerosis (MS) showed alterations in all individuals, consistent with mild cognitive impairment but including at least one test reaching the dementia threshold in 96%. 19 Compared with arthritis controls matched for pain severity and duration, depression and educational level, MMF patients displayed distinctive impairment of visual memory, working memory and dichotic listening, a pattern suggestive of cortico-subcortical organic damage involving fronto-parieto-thalamo-striatal areas, with deep white matter alterations. 19 Very similar cognitive alterations have been documented in workers exposed to inhaled Al fumes or powder. [20] [21] [22] These alterations are also reminiscent of those described in HIV-or HCV-infected (hepatitis-C virus) individuals. 19 In addition to CFS, 15-20% of patients with MMF concurrently develop an autoimmune disease, the most frequent being MS-like demyelinating disorders, 23, 24 Hashimoto's thyroiditis, and diffuse dysimmune neuromuscular diseases, such as dermatomyositis, necrotizing autoimmune myopathy, myasthenia gravis, and inclusion body myositis. Even in the absence of overt autoimmune disease, low titres of various autoantibodies, increased inflammatory biomarkers, and abnormal iron status are commonly detected. 4 Taken individually, none of the clinical manifestations commonly associated with persistent MMF is specific to a given cause. Combination of chronic myalgias, fatigue, and cognitive dysfunction is consistent with CFS, 18 a poorly understood condition also known as myalgic encephalomyelitis, 25 which may be triggered by various infectious and non-infectious agents. We previously noted the closely similar structure of symptoms in individuals with MMF and with the so-called Gulf war syndrome, 4 which is increasingly recognized as being linked to multiple vaccinations, 26, 27 with special emphasis put on anthrax vaccine, an alumadjuvanted vaccine administered in six shots, which was recently shown also to induce MMF. 13 On these grounds, we propose that MMF-associated symptoms should be considered as an adjuvant-induced syndrome. 16, 28 Therefore, we fully support the term ASIA (autoimmune/inflammatory syndrome induced by adjuvants) coined by Pr Shoenfeld to designate these symptoms, regardless of the nature of the immunological adjuvant involved (alum, silicone gel, viral components, etc.). 5 Handling and transport of poorly soluble nanomaterials by phagocytes: a possible clue for understanding MMF and ASIA For decades, aluminium oxyhydroxide has been the most commonly used adjuvant in human and veterinary vaccines. The mechanism by which it stimulates the immune response remains incompletely understood. 29 Imbalance between the huge number of alum-vaccine receivers and the small number of biopsyproven MMF cases strongly suggests that individual susceptibility factors play a crucial role in intolerance to alum. In rats, the genetic background strongly influences the size of lesions induced by i.m. injection of alum. 6 Adverse response to alum injection may also depend on susceptibility genes, such as HLA-DRB1*01, that may favour the development of autoimmune diseases. 30 Thus, aluminium likely represents one environmental factor able to trigger adverse effects in individuals with as yet largely unknown susceptibility genes. In keeping with this view, several closely related conditions have been shown to be associated with Al overload, including MMF, 14 idiopathic CFS, 31 and MS. 32 Moreover, strong suspicion of a possible link between Gulf war syndrome and alum administration has been experimentally supported. 33 Quite logically, questions are currently burgeoning about the exact safety level of aluminium adjuvants. 34 However, if biopersistence of the adjuvant in the body is a priori undesirable, the exact significance of MMF remains uncertain, since a conceptual link is still missing between the observed persistence of particle-loaded macrophages (MPs) at the site of previous immunization and the systemic, especially neurological, clinical manifestations. Alum is potentially highly neurotoxic, 33 but it is used at concentrations viewed as an acceptable compromise between adjuvanticity and toxicity by industry and regulatory agencies. In fact, the potential toxicity of alum will be influenced by whether the bioactive nanomaterial remains localized at injection points or scatters and accumulates in distant organs and tissues. Characterization of the fate of i.m. injected particles is therefore crucial for understanding the pathophysiology of MMF and related disorders.
A reference study based on isotopic 26 Al showed poor 26 Al clearance in the urine after i.m. injection of isotopic alum to rabbits (6% at d28 endpoint), and detected 26 Al, in an unknown form, in lymph nodes, spleen, liver, and brain. 35 However, as for other slowly biodegradable nanomaterials, the biodistribution of alum particles following injection into muscle is currently unknown.
Aluminium oxyhydroxide is composed of micron/ submicron-sized aggregates of nano-sized (ca. 13 nm) particles, and these aggregates were initially believed to remain extracellular until their complete solubilization in interstitial fluids. 35 We now know that quite the reverse is the case and that antigen-presenting cells (APCs) avidly take up alum particles, 36 and, in so doing, become long-lived cells 37 and impede alum solubilization. 2 Inflammatory monocytes (MOs) are attracted into muscle by danger signals, becoming macrophages and MO-derived dendritic cells (DCs), before migrating to the draining lymph nodes (DLNs). 38 Since one function of migratory DCs is to transfer antigenic material to a large network of distant resident APCs, we examined whether fluorescent nanomaterials injected into muscle could translocate to distant organs as part of a general mechanism linked to phagocytosis.
Preliminary results have substantiated this view. 39, 40 We observed that fluorescent surrogates of alum particles injected into mouse muscle were rapidly taken up by macrophages to form a MMFlike granuloma. An important proportion of particles escaped the injected muscle, mainly within immune cells, gaining access to the regional lymph nodes. Then particle-loaded cells exited the lymphatic system to reach the bloodstream (presumably through the thoracic duct, a terminal lymphatic vessel plugged to the subclavian vein), allowing them to gain access to distant organs such as spleen, liver and, eventually, brain. Using lymph node ablation and genetically manipulated animals, we documented that systemic biodistribution of particles injected into muscle necessitates early cell loading in muscle or lymph nodes, and crucially depends on the presence of attracting signals for monocytes (namely the MCP-1/CCL2 chemokine) in tissues. Thus, immune cells loaded with alum-like particles circulate after the i.m. injection and can reach distant tissues such as brain, especially if they produce attracting signals for inflammatory cells or exhibit weak blood brain barrier (BBB). 39, 40 This may also apply to other poorly degradable nanomaterials such as silicone, another compound suspected of causing ASIA. 5 Of course, much remains to be done to determine whether, in what conditions, and to what extent alum and other mineral particles gaining access to the brain by a Trojan horse mechanism, as HIV and HCV particles do, can cause significant inflammatory and neurotoxic damage.
In conclusion, MMF revealed an almost complete lack of knowledge on the fate, systemic diffusion, and long-term safety of alum particles. On the grounds of our clinical and experimental data, we believe that increased attention should be paid to possible long-term neurological effects of continuously escalating doses of alum-containing vaccines administered to the general population. Special emphasis should be put on individuals with immature/altered BBB or inflammatory states.
